http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20150107695-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ccce54679e83d46d0c13dd1e7e1beddd |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-35 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-28 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-35 |
| filingDate | 2015-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d7cb3d6f1c7af48304c6cc5cb402e02d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d2ea55360513f72b20b8c168091acb0a |
| publicationDate | 2015-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20150107695-A |
| titleOfInvention | Compositions comprising adipose-derived mesenchymal stem cell overexpressing gcp-2 gene for treating ischemic disease |
| abstract | The present invention relates to adipose-derived mesenchymal stem cells (ASCs) overexpressing GCP-2 (Granulocyte chemotactic protein-2) gene. The lipid mesenchymal stem cells according to the present invention overexpress the VEGF-A and HGF genes to promote angiogenesis, reduce the left ventricular end diastolic diameter (LVEDD) and the left ventricular end systolic diameter (LVESD) ejection fraction to improve cardiac function and increase vascular density in the ischemic area and may be useful for the treatment of ischemic diseases. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018236131-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020524165-A |
| priorityDate | 2015-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 293.